Abstract
Anticytokine autoantibodies represent an emerging mechanism underlying the pathogenesis of immune deficiency. In contrast to primary immune deficiencies caused by genetic mutations that are present from birth and tend to manifest early and irreversibly, immune deficiency resulting from anticytokine autoantibodies have a later onset and variable course. This group of diseases is characterized by the development of one or a few, high-titer, and high-affinity anticytokine autoantibodies whereby the disease manifestations are a consequence of the cytokine pathway that is inhibited. Further evidence supporting their role in pathogenesis is found in patients who have genetic defects within the same signaling pathway and have similar disease phenotypes. This chapter will outline the syndromes associated with autoantibodies directed against granulocyte macrophage–colony-stimulating factor (GM-CSF); interferon (IFN)-γ; interleukin (IL)-17A, IL-17F, IL-22 and IL-6.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
